6533b86dfe1ef96bd12c9739
RESEARCH PRODUCT
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
Maximilian HochmairBalazs HalmosBenjamin LevyAngela MärtenEng Huat TanFilippo De MarinisMartin SebastianJames Chih-hsin YangSven WindIsamu OkamotoDavid P. CarboneDan MasseyR. ShahNicolas J. DickgreberMartin SchulerVera HirshNobuyuki YamamotoKenneth J. O'byrneTony MokMyung-ju Ahnsubject
Pulmonary and Respiratory MedicineBrachial Plexus NeuritisOncologyCancer Researchmedicine.medical_specialtybusiness.industryAfatinibMedizinnon-small cell lung cancer (NSCLC)HematologyPharmacologymedicine.diseasestomatognathic diseasesTolerabilityOncologyEgfr mutationDose adjustmentInternal medicinemedicineIn patientbusinessmedicine.drugdescription
8073 Background: Afatinib 40 mg/day (oral) is approved for the treatment of pts with advanced EGFRm+ NSCLC. Dose adjustment is recommended according to pre-defined tolerability criteria. We perform...
year | journal | country | edition | language |
---|---|---|---|---|
2015-01-01 |